Diseases & Conditions Archive

Q. I experienced a minute of blurred vision during a headache today. Is that cause for concern?

A. While temporary blurred vision usually does not indicate a serious underlying health problem, on occasion it can. In people over age 60, I am more concerned about that symptom, because it can be sign of a transient ischemic attack (TIA), also called a ministroke. The fact that your vision problem accompanied a headache could well indicate that you are suffering from a common type of headache—migraine. Migraines don't threaten permanent damage to your brain, whereas a TIA is a sign that a person is at risk for an impending stroke. Strokes can cause permanent brain damage. If you are younger than 60, if you have had headaches accompanied by visual problems multiple times in the past, or if you have been diagnosed as having migraine headaches, I'd feel even more confident that your symptoms are caused by this condition.

Daily aspirin use has increased among U.S. adults, according to a survey published May 2015 in the American Journal of Preventive Medicine. The survey asked more than 2,500 people ages 45 to 75 about their current aspirin use. The overall use was 52%, up from 41% in a similar survey in 2004. The most common reasons for taking daily aspirin were prevention of heart attack and stroke. Eighteen percent of aspirin users cited cancer prevention as their reason for taking aspirin. And while most users said they'd talked to their doctor before starting aspirin therapy, 25% of the respondents had not. That finding is troubling, since aspirin is a blood thinner. "Aspirin can increase the risk of bleeding in the brain or elsewhere in the body. This risk might be justified if there is a good reason for aspirin use, but might be entirely unjustifiable if not. That is why I always recommend discussing any medication or supplement use with one's primary care provider," says Dr. Natalia Rost, associate professor of neurology at Harvard Medical School. 

Image: Thinkstock

As we reported in March, sleep apnea and other sleep breathing problems are associated with the development of dementia. Now a study published online April 15, 2015, by Neurology finds that sleep breathing problems are associated with an earlier onset of the decline in thinking skills.

Researchers analyzed the medical histories of about 2,500 people ages 55 to 90 and found that people with sleep breathing problems were diagnosed with mild cognitive impairment (a decline in thinking skills) an average of 10 years earlier than people who didn't have those problems. The encouraging news: people who treated their sleep breathing problems with a continuous positive airway pressure (CPAP) machine were diagnosed with mild cognitive impairment about 10 years later than people whose problems were not treated. The study doesn't prove a cause-and-effect relationship, but it does offer hope. "CPAP improves the quality of sleep in people with sleep-disordered breathing. Healthy sleep is an important time for our brains to accomplish critical 'housekeeping' tasks. One of these tasks is clearing beta-amyloid, one of the main proteins associated with Alzheimer's disease," says Dr. Scott McGinnis, an instructor in neurology at Harvard Medical School.

I had shingles in 2005 and haven?t had a shingles shot. I haven?t been able to find any studies that indicate whether a shot is feasible for people who have already had shingles. What do you recommend?

People with high blood pressure could benefit from a B vitamin known as folate if they are not getting enough from their diets, according to a study in The Journal of the American Medical Association (JAMA).

The study included more than 20,000 adults in China with high blood pressure who had never had a stroke or heart attack. Participants who took folate supplements along with a blood pressure medication had fewer strokes over the four-and-one-half-year trial than those who only took the medication.

Many different medications can potentially harm the liver, so doctors sometimes do liver function tests to ensure safety. The worst-case scenario is liver failure, but when this happens, the cause is usually not prescription medications, but rather the over-the-counter painkiller acetaminophen (Tylenol) or herbal supplements, according to a study in Gastroenterology.

Researchers scrutinized 5.4 million records of patients in the Kaiser Permanente Northern California system from 2004 to 2010. They identified only 62 cases of liver failure, 32 of which were linked to medications. This may not precisely reflect national rates, but it does suggest that liver failure from medications is relatively uncommon.

A fainting spell can be inconsequential, or it can signal a serious health issue. It's important to learn why you faint.

Many procedures require anesthesia, and which of the four types you have can affect your recovery.

If you've ever had a tooth filled without Novocaine, you know the difference anesthesia can make. Anesthesia—whether it numbs your mouth or puts you into a full sleep—is designed to keep you comfortable during a procedure that otherwise might be hard to tolerate physically, emotionally, or both. "We have four goals: to see that you have no pain, that you're drowsy or unconscious, that your body is still so that the surgeon can work on it, and that you aren't left with bad memories of the procedure," says Dr. Kristin Schreiber, an anesthesiologist at Harvard-affiliated Brigham and Women's Hospital.

There are four basic kinds of anesthesia—local, which is typically administered to numb a small area; regional, which numbs a larger area, like your hand, arm, or foot; neuraxial (spinal or epidural), which is injected near the spine and numbs the lower half of your body; and general, which works in the brain to render you completely unconscious and unable to sense pain. The type used depends upon the procedure you're having, your state of health, and, often, your preferences.

Researchers from the biotechnology company Biogen have reported that a new drug reduced the amount of amyloid plaques—the brain deposits associated with dementia—and slowed cognitive decline in people with early Alzheimer's disease. They presented the report March 20, 2015, at the International Conference on Alzheimer's and Parkinson's Diseases in Nice, France.

The researchers studied 166 people ages 50 to 90 who had been diagnosed with mild Alzheimer's. The participants were randomly assigned to receive either a placebo or one of four different doses of the drug aducanumab—an antibody that attaches to amyloid deposits and turns the immune system on them.